Massive study tests new clot-buster for deadly lung condition
NCT ID NCT07245927
First seen Jan 11, 2026 · Last updated May 23, 2026 · Updated 26 times
Summary
This study is testing a drug called non-immunogenic staphylokinase in 20,000 adults with a massive blood clot in the lungs (pulmonary embolism). The goal is to see if the drug can safely break up the clot and lower the risk of death or other serious problems. Participants will receive a single injection of the drug and be followed for 30 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY EMBOLISM ACUTE MASSIVE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
E.I. Chazov National Medical Research Center of Cardiology
RECRUITINGMoscow, 121552, Russia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.